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Viral nucleic acids often trigger an innate immune
response in infected cells. Many viruses, including
hepatitis C virus (HCV), have evolved mechanisms
to evade intracellular recognition. Nevertheless,
HCV-permissive cells can trigger a viral RNA-,
TLR7-, and cell-contact-dependent compensatory
interferon response in nonpermissive plasmacytoid
dendritic cells (pDCs). Here we report that these
events are mediated by transfer of HCV-RNA-con-
taining exosomes from infected cells to pDCs. The
exosomal viral RNA transfer is dependent on the
endosomal sorting complex required for transport
(ESCRT) machinery and on Annexin A2, an RNA-
binding protein involved in membrane vesicle traf-
ficking, and is suppressed by exosome release
inhibitors. Further, purified concentrated HCV-RNA-
containing exosomes are sufficient to activate
pDCs. Thus, vesicular sequestration and exosomal
export of viral RNAmay serve both as a viral strategy
to evade pathogen sensing within infected cells
and as a host strategy to induce an unopposed
innate response in replication-nonpermissive by-
stander cells.
INTRODUCTION
Upon sensing invading viruses, host cells trigger signaling
events that ultimately lead to the secretion of type I interferons
(IFNs) and to the expression of an array of IFN-stimulated genes
(ISGs) (Kawai and Akira, 2009). ISGs are important effectors
that suppress viral spread by blocking the viral life cycle at
multiple levels (Sadler and Williams, 2008). Specific motifs
known as pathogen-associated molecular patterns (PAMPs),
which include viral nucleic acids, are recognized by pattern
recognition receptors (PRRs) that mobilize the innate immune
response (Kawai and Akira, 2009). These receptors can be
cytoplasmic (e.g., retinoic inducible gene-I (RIG-I)-like receptors
(RLRs) (Kawai and Akira, 2009; Loo and Gale, 2011) and NOD-
like receptors (Kawai and Akira, 2009) or endosomal (e.g., Toll-558 Cell Host & Microbe 12, 558–570, October 18, 2012 ª2012 Elsevlike receptors [TLRs] [Blasius and Beutler, 2010; Kawai and
Akira, 2011]). Thus, the current concept of virus-induced innate
immune signaling is that recognition of viral nucleic acids typi-
cally occurs within cells that are either productively infected
or have internalized viral particles (Blasius and Beutler, 2010;
Loo and Gale, 2011).
Many viruses deploy mechanisms designed to avert, subvert,
or evade pathogen-sensing pathway (Versteeg and Garcı´a-
Sastre, 2010). For example, the hepatitis C virus (HCV) has
evolved a potent strategy that precludes type 1 IFN induction
by infected hepatocytes (Cheng et al., 2006; Liang et al., 2008).
Specifically, the NS3-4A protease of HCV inactivates MAVS/
IPS-1/cardif, the signaling adaptor of the RLR sensing pathway,
by proteolytic cleavage (Foy et al., 2005; Horner et al., 2011;
Li et al., 2005b; Loo et al., 2006; Meylan et al., 2005). Further-
more, cleavage of the TIR-domain-containing adaptor-inducing
IFN-b (TRIF) adaptor by NS3-4A abrogates signaling transduc-
tion induced by endosomal TLR3 (Li et al., 2005a; Wang et al.,
2009). However, despite these inhibitory mechanisms, HCV
infection strongly triggers the expression of ISGs in the liver of
experimentally HCV-infected chimpanzees (Bigger et al., 2001,
2004; Su et al., 2002) and naturally HCV-infected humans (Alter
and Seeff, 2000). Therefore, these results suggest the existence
of alternative pathogen-sensing mechanisms that are not
opposed by viral evasion mechanisms.
In previous studies, we (Takahashi et al., 2010) and others
(Dental et al., 2012; Zhang et al., 2012) recently reported that
HCV-infected cells trigger plasmacytoid dendritic cells (pDCs)
to produce type 1 IFN. We found that pDC-activation occurs
in a cell-cell-contact- and TLR7-dependent manner that is
dependent on the intracellular HCV-RNA level of cocultured in-
fected cells (Takahashi et al., 2010). In addition, we showed
that induction of the IFN response by pDCs is independent of
virus production because HCV subgenomic replicon (SGR) cells
that replicate the viral RNA but cannot produce infectious
virus particles can also trigger pDCs to produce type 1 IFN
(Takahashi et al., 2010).
Many cell types release membrane-enclosed microvesicles
into the extracellular milieu, the best-characterized of which
are 40–100 nmendosome-derived secreted vesicles (exosomes;
The´ry et al., 2009) that have been shown to transfer functional
microRNA and messenger RNA (mRNA) to recipient cells
(Kosaka et al., 2010; Meckes et al., 2010; Pegtel et al., 2010;
Skog et al., 2008; Valadi et al., 2007). Based on previous reportsier Inc.
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nomic viral RNA (Pietschmann et al., 2002), that exosome-like
structures are present in the supernatant of HCV-infected cells
(Gastaminza et al., 2010), and that HCV-RNA-containing exo-
somes are detected in the plasma of HCV-infected patients
(Masciopinto et al., 2004), we reasoned that HCV RNA might
be secreted within exosomal vesicles from HCV-infected cells
and trigger IFN-a production by pDCs.
Here we report that exosomes are a previously unrecognized
PAMP carrier that can mediate cell-to-cell transfer of immunos-
timulatory viral RNA from infected cells to cocultured pDCs and
trigger the production of type 1 IFN. In addition, we define the
cellular mechanisms responsible for biogenesis of the PAMP-
containing exosomes. These results demonstrate a previously
unsuspected aspect of the innate host response in which in-
fected cells, whose pathogen-sensing machinery is inhibited
by viral proteins, utilize exosomes to transfer viral RNA to neigh-
boring noninfectible cells that are specifically designed to
respond to viral RNA.
RESULTS
Exosomal Transfer of Viral RNA from HCV-Infected
and HCV-SGR Cells to pDCs Triggers IFN-a Production
HCV-infected Huh-7.5.1c2 (Pedersen et al., 2007) cells were co-
cultivatedwith primary human, peripheral blood-derived pDCs in
the presence or absence of two structurally unrelated neutral
sphingomyelinase inhibitors (GW4869 and spiroepoxide) that
are well-known inhibitors of exosome release (Chairoungdua
et al., 2010; Kogure et al., 2011; Kosaka et al., 2010, 2012;
Trajkovic et al., 2008; Yuyama et al., 2012). Both GW4869 and
spiroepoxide completely abolished (>2 log reduction) IFN-a
secretion by the pDCs (Figure 1A) without reducing the intra-
cellular HCV-RNA content of the infected cells (Figure 1B) and
with little (<5-fold) or no reduction of infectious HCV particle
production (Figure 1C). Similar results were also obtained using
Huh-7.5.1 cells and parental Huh-7 cells (Figures S1A–S1C
available online). Remarkably, both compounds also abrogated
IFN-a production by pDCs cocultured with HCV-SGR cells (Fig-
ure 1D) in a dose-dependent manner (Figure S1D) that correlated
with the magnitude of inhibition of exosome production (Fig-
ure S1F) and exosomal HCV-RNA (Figure S1G) release. Neither
compound inhibited HCV-RNA replication in the SGR cells
(Figures 1E and S1E), nor did they inhibit pDC IFN-a production
that was triggered by R848 (a specific TLR7 agonist; Kawai and
Akira, 2009; Figures 1F and S1D), thus ruling out potential
nonspecific effects of these compounds on pDCs.
The SGR cell results indicated that the pDC immunostimula-
tory signal could be transmitted via a virus particle-independent
pathway. To corroborate this assumption and to determine
whether HCV RNA is transmitted to cocultured pDCs even in
the absence of virus production, we used a highly sensitive
HCV-RNA-specific fluorescence in situ hybridization (FISH)
assay to monitor the presence of HCV RNA in infected cells,
SGR cells, and cocultivated pDCs. As expected, the intensity
of the HCV-RNA signal was much stronger in infected cells (Fig-
ure 2A, left panel) than in SGR cells (Figure 2B, left panel), reflect-
ing the former’s 10-fold greater content of HCV RNA (data not
shown). Nonetheless, HCV RNA (green) was readily detected inCell HostpDCs after 20 hr of cocultivation with HCV-SGR cells (Figure 2C,
middle panel). Combined HCV-RNA FISH and IFN-a immuno-
staining revealed that HCV RNA was detected in 45.5% (10/22)
of IFN-a-positive pDCs and 8.6% (9/105) IFN-a-negative pDCs
after cocultivation with SGR cells (Figure 2D) but was never
detectable (0/61) in pDCs cocultured with HCV-negative cells
(not shown). Collectively, these results suggest that both HCV-
infected cells and SGR cells release HCV-RNA-containing exo-
somes that transfer HCV RNA to cocultured pDCs and trigger
IFN-a production. The exosomal nature of the transfer process
is underscored by the transfer of HCV RNA to pDCs by SGR cells
in which virus particle production cannot occur.
HCV RNA Is Selectively Packaged within Exosomes
that Trigger pDC IFN-a Production
Exosomes are endosome-derived secreted vesicles (The´ry et al.,
2009) that are formed by membrane invagination within multive-
sicular bodies (MVBs) and exocytosed by fusion of the MVB
membrane with the cell surface membrane (Bobrie et al., 2011;
The´ry et al., 2009). HCV-RNA-containing exosomes cannot be
readily distinguished or physically separated from infectious
HCV particles by conventional biophysical techniques because
they share similar buoyant densities and sedimentation veloci-
ties (Lindenbach et al., 2005; Meckes and Raab-Traub, 2011);
therefore, we used HCV-SGR cells in all subsequent studies to
analyze the exosome-mediated transfer process without the
potentially confounding impact of coexisting virus particles.
We view the results of these SGR-cell-based studies as being
representative of HCV-infected cells because both infected
and SGR cells trigger IFN-a production by pDCs in a TLR-7-
dependent and cell-cell-contact-dependent manner (Takahashi
et al., 2010) that in both cases is antagonized by exosome
release inhibitors (Figure 1).
First, we asked whether there was evidence that HCV RNA
might colocalize in HCV-SGR cells with proteins that are known
to be enriched in exosomes (e.g., CD63, CD81, and CHMP4B;
Bobrie et al., 2011; The´ry et al., 2009). As shown in Figure 3,
HCV RNA colocalized with a subset of CD63-, CD81-, and
CHMP4B-positive signals in HCV-SGR cells, consistent with
the notion that HCV RNA could be incorporated into intracellular
vesicles destined to become exosomes.
Next, we asked whether membrane-bound HCV RNA is
released into the supernatant of HCV-SGR cells that do not
produce HCV structural proteins and thus cannot produce virus
particles. As shown in Figures 4A–4C, the supernatant of HCV-
SGR cells contained >106 copies per milliliter of HCV RNA that
was resistant to digestion by ribonuclease A (RNase) unless it
was also exposed to NP40. These results suggested that the
secreted HCV RNAwas contained within lipid membrane-bound
vesicles. Additionally, we showed that the extracellular HCVRNA
was not merely present in cellular debris, since it was >100-fold
more abundant than the extracellular glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) mRNA content in the same
supernatants (Figure 4D), whereas the intracellular HCV-RNA
content was less abundant than GAPDH mRNA in the corre-
sponding SGR cells (Figure 4D).
Finally, exosomes were prepared from the supernatants of
HCV-SGR cells and analyzed for their protein and RNA content
and their ability to trigger IFN-a production by pDCs. As shown& Microbe 12, 558–570, October 18, 2012 ª2012 Elsevier Inc. 559
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Figure 1. Inhibition of pDC Activation Triggered by HCV-Infected and SGR Cells by Exosome Release Inhibitors
(A–C) Quantification of IFN-a in supernatants of pDCs cocultured with HCV-infected Huh-7.5.1c2 cells (moi of 1 for 48 hr) that were treated or not with exosome-
release inhibitors GW4869 or spiroepoxide (10 and 5 mM, respectively) throughout the course of the coculture (A). Uninfected Huh-7.5.1c2 cells are referred to as
control (cont) cells. The hatch marks (#) indicate results below the limit of detection of the IFN-a ELISA (i.e., 12.5 pg/ml). In parallel, the intracellular HCV-RNA
levels (B) and extracellular infectious virus production (C) of HCV-infected cells treated with exosome release inhibitors were analyzed. Results are representative
of two independent experiments, each performed in triplicate. Error bars represent the mean ± SD.
(D) Quantification of IFN-a in supernatants of pDCs cocultured with HCV-SGR Huh-7.5.1c2 cells after treatment with exosome-release inhibitors GW4869 or
spiroepoxide (treatment with 10 and 5 mM, respectively) throughout the course of the coculture. HCV-negative Huh-7.5.1c2 cells served as controls (cont cells).
(E) Intracellular HCV-RNA levels in HCV-SGR cells treated for 24 hr with exosome release inhibitors.
(F) Parallel pDC/control cell cocultures were incubated with the TLR-7 ligand agonist R848 and supernatants were analyzed for IFN-a. Results in (D)–(F) are
representative of three independent experiments, eachperformed in triplicate. Bar graphsdepict themean±SD. The treatment conditions (i.e., incubation timeand
concentration) were exactly the same for the analysis of IFN-a production, HCV-RNA replication, and extracellular infectious virus production. See also Figure S1.
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Exosomes Transfer HCV RNA to pDCs and Trigger IFNin Figures 5A, S1F, and S2A, the concentrated exosome prepa-
rations were specifically enriched in the exosome markers CD63
and CD81 relative to nonexosomal cellular proteins EEA1 (an
endosome marker), calnexin (an ER marker), COX IV (a mito-
chondrial marker), and ARF1 (a Golgi marker). Importantly, the
concentrated exosome preparations contained >105 copies of
HCV RNA (per microgram of total protein) that were >150-fold
concentrated relative to the amount of HCV RNA in the corre-
sponding unconcentrated SGR-cell supernatants (i.e., approxi-
mately 4–83 108 versus 2–43 106 GE/ml, respectively; Figures
S1G and 4A, respectively), >100-fold enriched relative toGAPDH
mRNA (Figure 5B), and fully protected from RNase digestion
unless they were also treated with NP40 (Figure 5B). Interest-560 Cell Host & Microbe 12, 558–570, October 18, 2012 ª2012 Elsevingly, northern blot analysis of the exosome-associated RNA
revealed that the HCV RNA comigrated with the dominant
HCV-RNA species present in the corresponding HCV-SGR cells
(Figure 5C), suggesting that it represented a full-length HCV-
SGR genome (i.e., 8,024 nucleotides). Importantly, the viral
NS4B and NS5A proteins and calnexin, all of which are known
to be present in HCV replication complexes (Backes et al.,
2010; El-Hage and Luo, 2003), were not detected in concen-
trated exosome preparations (Figure S2A). Collectively, these
results suggest that the RNase-resistant extracellular HCV
RNA reflects the release of viral RNA-containing exosomes
from SGR cells rather than HCV replication complexes
that, theoretically, could be present in cellular debris in theier Inc.
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Figure 2. HCV RNA Is Transferred from HCV-SGR Cells to pDCs
(A) Specificity of HCV-RNA detection (green) by FISH in HCV-infected Huh-7.5.1c2 cells that expressed high levels of HCV RNA (left panel), that were treated with
the HCV polymerase inhibitor 20-C-methyladenosine (5 mM for 24 hr; middle panel) and in uninfected Huh-7.5.1c2 cells (no HCV; right panel). Nuclei are stained
with Hoechst dye (blue).
(B and C) Projection (B) and consecutive Z-axis sections (C) of pDC cocultured with HCV-SGR Huh-7.5.1c2 cells (3.5-fold magnification of the white box in [B]).
Green: HCV RNA; red: IFN-a protein; blue: nuclei. HCV RNAs inside pDC are indicated by white arrows. Of note, FISH HCV-RNA signals are lower in HCV-SGR
cells because they contain10-fold less HCVRNA than infected cells, and in addition, FISH signals are reducedwhen combinedwith immunofluorescent staining
(data not shown). Similar results were obtained in five independent experiments.
(D) Summary table showing the fraction of total cocultured pDCs that contain HCV RNA.
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Figure 3. Colocalization of HCV RNA, Exosome Markers in HCV-SGR Cells
(A–C) Detection of HCV RNA (red); CD63 (A, green), eGFP-CD81 (B, green), and FLAG-CHMP4B proteins (C, green); and nuclei (blue) in HCV-SGR Huh-7.5.1c2
cells. Panels 2–4 correspond to a 3.6-fold magnification of the white box in #1 in each row. The arrows indicate HCV RNA in CD63-, CD81-, or CHMP4B-positive
compartments. The frequencies of HCV-SGR cells in which HCV RNA colocalized with CHMP4B, CD81, and CD63 were 25/29, 38/56, and 17/24, respectively.
Results are representative of three independent experiments.
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Exosomes Transfer HCV RNA to pDCs and Trigger IFNculture supernatants. Additionally, as shown in Figure S2B,
buoyant density separation analysis revealed that the extracel-
lular HCV RNA cofractionated with exosome markers (CD81
and CD63) and displayed the expected density profile of
exosomes (1.10–1.19 g/ml; Meckes and Raab-Traub, 2011)
rather than HCV replicase complexes (>1.17 g/ml; Ferraris
et al., 2010; Villanueva et al., 2010) or apoptotic bodies (1.24–
1.28 g/ml; Meckes and Raab-Traub, 2011). Importantly, highly
concentrated exosomes prepared from HCV-SGR cells trig-
gered IFN-a production by pDCs in a dose-dependent manner
(Figure 5D). Collectively, these results suggest that HCV RNA
is selectively packaged in exosomes that transfer it to pDCs
that respond by secreting IFN-a.
ESCRT Proteins Are Required for HCV-Infected
and HCV-SGR Cells to Trigger pDC IFN-a Production
The endosomal sorting complex required for transport (ESCRT)
machinery is known to be required for exosome biogenesis562 Cell Host & Microbe 12, 558–570, October 18, 2012 ª2012 Elsev(Baietti et al., 2012; Fe´vrier and Raposo, 2004; Tamai et al.,
2010). To determine whether it is also required for generation
of the pDC-activating signal by HCV-infected Huh-7.5.1c2
cells and SGR cells, we used lentivirus vector-based small
hairpin RNA (shRNA) transduction to inhibit the expression of
chromatin-modifying protein 4B (CHMP4B; Figure 6A, upper
left panel), a component of complex III of the ESCRT machinery
(Hurley and Hanson, 2010). Importantly, the ability of CHMP4B-
downregulated HCV-SGR cells to stimulate IFN-a production by
cocultured pDCswas strongly inhibited (Figure 6A,middle panel,
lanes 4 and 5), whereas their ability to support HCV replication
was unchanged (Figure 6A, lower panel, lanes 4 and 5). In
contrast, shRNAs that target either an irrelevant (green fluores-
cent protein [GFP]; Figure 6A, middle panel, lane 3) or an unre-
lated nonESCRT protein (Atg4B; Figure 6A, middle panel,
lane 6) did not impair IFN-a production by cocultured pDCs. To
confirm these results, we asked whether tumor susceptibility
gene 101 (TSG101) expression, a critical component of complex Iier Inc.
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Figure 4. RNase-Resistant HCV RNA Is Secreted from HCV-SGR
Cells
(A–C) HCV-RNA levels in precleared supernatants from HCV-SGR Huh-
7.5.1c2 cells (A: n = 4,mean ± SD; C: n = 2, mean ± SD), and in vitro transcribed
HCV RNA (B: n = 3, mean ± SD) were treated with RNase, NP40, and/or RNase
inhibitor, as indicated. The hatchmarks (#) indicate results below the detection
limit of the assay (i.e., 500 HCV GE/ml). GE, genome equivalents.
(D) HCV and GADPH RNA levels in precleared supernatants from HCV-SGR
Huh-7.5.1c2 cells (extracell) either untreated or treated with RNase, NP40, and
untreated SGR cell RNA (intracell) as indicated. Error bars represent the
mean ± SD (n = 3); paired Student’s t test, **p < 0.005.
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Exosomes Transfer HCV RNA to pDCs and Trigger IFNof the ESCRT machinery (Hurley and Hanson, 2010), was
required for the HCV-SGR cells to trigger pDC IFN-a production.
Again, downregulation of TSG101 expression in HCV-SGR cells
(Figure 6B, upper panel) abolished their ability to trigger pDC
IFN-a production (Figure 6B, middle panel) without inhibitingCell HostHCV-RNA replication (Figure 6B, lower panel). These results
strongly suggest that MVBs play a key role in the production of
the pDC-activating signal by SGR cells.
Importantly, we confirmed these results by demonstrating that
shRNA-mediated downregulation of CHMP4B and TSG101
expression in HCV-infected cells (Figure 6C) either abrogated
or markedly impaired (by 60-fold) their ability to trigger pDC
IFN-a production (Figure 6D, upper panel), and, consistent with
previous reports (Ariumi et al., 2011; Corless et al., 2010; Tamai
et al., 2012), had little or no impact on HCV-RNA replication
(Figure 6D, lower panel), and a modest effect (i.e., <2- to 4-fold
reduction) on infectious virus production (Figure 6E). Similar
results were obtained using Huh-7.5.1 cells and parental Huh-7
cells (Figure S3). Collectively, these results indicate that the
ESCRT machinery is required for HCV-infected and SGR cells
to activate pDCs, suggesting that MVBs are required for this
process and reinforcing the notion that the pDC activating signal
is exosomal HCV RNA.
ANXA2 Is Required for HCV-Infected and HCV-SGR
Cells to Trigger pDC IFN-a Production
Annexin A2 (ANXA2) is an RNA-binding protein (Aukrust et al.,
2007; Filipenko et al., 2004) that plays a key role in membrane
vesicle trafficking and MVB biogenesis (Gerke et al., 2005;
Mayran et al., 2003; Morel et al., 2009). Interestingly, recent
reports indicated that ANXA2 is recruited to HCV replication sites
where it regulates virus particle production (Backes et al., 2010;
Saxena et al., 2012). Therefore, we used shRNA-mediated
knockdown to determine whether ANXA2 is required for HCV-
infected Huh-7.5.1c2 cells and SGR cells to trigger IFN-a
production by cocultured pDCs. As shown in Figure 7, ANXA2
downregulation in HCV-SGR cells (Figure 7A) abolished their
ability to trigger IFN-a production by cocultured pDCs (Figure 7B)
without inhibiting HCV-RNA replication (Figure 7C), the latter
confirming the results of Backes et al. (2010). The ANXA2
requirement for pDC activation was confirmed by the restoration
of pDC activation by ANXA2 shRNA-downregulated SGR cells
by ectopic overexpression of an ANXA2 encoding shRNA-resis-
tant RNA (Figure 7B). Consistent with these results, downregula-
tion of ANXA2 expression in HCV-infected cells (Figure 7D)
decreased their ability to trigger IFN-a production by cocultured
pDCs by >20-fold (Figure 7E) without inhibiting HCV-RNA
replication (Figure 7F) or significantly (<2.5-fold) suppressing
infectious virus production (Figure 7G). Similar results were
obtained using Huh-7.5.1 cells and parental Huh-7 cells (Fig-
ure S4). Altogether, these results demonstrate that ANXA2 is
required for both HCV-SGR cells and HCV-infected cells to
trigger IFN-a production by pDCs, possibly by orchestrating
the recruitment of appropriate cellular and/or viral components
to generate the HCV-RNA-containing exosomes that trigger
the pDC IFN response.
DISCUSSION
pDCs function as sentinels of viral infection, predominantly via
recognition of single-stranded RNA and unmethylated CpG-
containing DNA by endosomal TLR7 and TLR9, respectively
(Reizis et al., 2011), and are a major IFN-a-producing cell type
in vivo (Asselin-Paturel et al., 2003; Cisse et al., 2008; Kumagai& Microbe 12, 558–570, October 18, 2012 ª2012 Elsevier Inc. 563
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Figure 5. Exosomes Prepared from HCV-
SGR Cell Supernatants Trigger IFN-a Pro-
duction by pDCs
(A) Comparison of exosome (CD63 and CD81) and
nonexosome (EEA-1, calnexin, and COX IV)
markers in exosomes prepared from HCV-SGR
Huh-7.5.1c2 cell supernatants and from the
corresponding whole-cell lysates (intracell) by
immunoblotting. The molecular weight markers
(MW, in kDa) are indicated to the right.
(B) Exosome preparations were treated with
NP40 and/or RNase and qRT-PCR results are
expressed as HCV GE or GAPDH mRNA copies
per mg of total protein. Error bars represent the
mean ± SD (n = 3).
(C) Northern blot analysis. The input copy number
of HCV and GADPH RNA determined by qRT-PCR
is indicated below each blot. Huh-7.5.1c2 cells
served as negative control (cont cells). NA, not
applicable.
(D) pDCs (4 3 105 cells) were incubated with
concentrated exosomes at varying HCV GE/pDC
ratios or with R848, a TLR7 agonist. The hatch
marks (#) indicate results below the limit of
detection of the IFN-a ELISA (12.5 pg/ml). Results
are representative of two independent experi-
ments. Error bars represent the mean ± SD. See
also Figure S2.
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stimuli typically occurs when they are infected by viruses such
as respiratory syncytial virus, influenza virus, and lymphocytic
choriomeningitis infection (Blasius and Beutler, 2010; Hornung
et al., 2004; Lee et al., 2007; Loo and Gale, 2011; Macal et al.,
2012), resulting in the rapid secretion of type 1 IFN in a response
that is up to 1,000-fold more vigorous than in other similarly
infected cell types (Liu, 2005).
In contrast to these conventional mechanisms for pDC activa-
tion, here we define a host strategy that ensures recognition of
infectious agents that on one hand defeat the pathogen-sensing
machinery in the cells they infect, and on the other hand do not
productively infect pDCs (Decalf et al., 2007). Using HCV as a
model, we demonstrate that HCV-permissive cells that do not
produce type 1 IFN because the HCV NS3/4A protease inter-
rupts the RLR and TLR signaling pathways in the cells (Cheng
et al., 2006; Foy et al., 2005; Horner et al., 2011; Li et al.,
2005a, 2005b; Liang et al., 2008; Loo et al., 2006; Meylan
et al., 2005; Wang et al., 2009) can selectively package immu-
nostimulatory viral RNA within exosomes that deliver their RNA
cargo to neighboring, HCV-nonpermissive (Decalf et al., 2007)
pDCs in a concentration-dependent manner that triggers an
antiviral IFN response. We suggest that this mechanism may
have evolved to protect the host against pathogens that, like
HCV, can blunt the IFN response in productively infected cells
(Versteeg and Garcı´a-Sastre, 2010).
To unambiguously dissect the exosomal transmission of im-
munostimulatory HCV RNA without the potentially confounding
effect of HCV-RNA-containing virus particles, in many experi-
ments we used SGR cells that replicate a subgenomic fragment
of viral RNA that encodes only the HCV nonstructural proteins564 Cell Host & Microbe 12, 558–570, October 18, 2012 ª2012 Elsevand thus cannot assemble virus particles. The results from those
experiments, as well as others performed in HCV-infected cells
using exosome release inhibitors and shRNA downregulation
of the ESCRT machinery and ANXA2, reveal that immunostimu-
latory HCV RNA is produced by SGR cells and infected cells,
packaged within exosomes, and transferred to cocultured
pDCs that it triggers to produce type I IFN. Exosome formation
is initiated in MVBs by invagination of endosomal membranes
and generation of intraluminal vesicles (ILV; Al-Nedawi et al.,
2008; Bobrie et al., 2011; Couzin, 2005; Fe´vrier and Raposo,
2004; Lie´geois et al., 2006). Importantly, HCV RNA colocalized
with CD63, CD81, and CHMP4B proteins, which are known to
be enriched in MVB (Figure 3), suggesting that HCV RNA is
directed to this cellular compartment by an as yet unknown
mechanism. The ESCRT machinery regulates membrane
budding and ILV formation at the late endosome level (Henne
et al., 2011; Raiborg and Stenmark, 2009), and ESCRT compo-
nents are thus involved in exosome biogenesis (Baietti et al.,
2012; Fe´vrier and Raposo, 2004; Tamai et al., 2010). Therefore,
one might speculate that ESCRT proteins, such as Tsg101 and
CHMP4B, may contribute to the processes of membrane
bending and abscission that direct HCV RNA to ILVs and exo-
somes. Alternatively, Tsg101 and CHMP4B may be indirectly
involved in endosomal compartments that require ESCRTs for
their architectural and functional integrity (Doyotte et al., 2005;
Razi and Futter, 2006).
Although exosomal transfer of functional cellular mRNA and
microRNA to recipient cells has been previously reported
(Kosaka et al., 2010; Meckes et al., 2010; Pegtel et al., 2010;
Skog et al., 2008; Valadi et al., 2007), to our knowledge, our
demonstration that exosomes can mediate the transfer ofier Inc.
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in a cell-cell-contact-dependent manner reveals a previously
unappreciated aspect of the innate immune response to viral
infection. In addition, it is conceivable that exosome-mediated
export of viral RNAmay have a variety of unexpected and poten-
tially alternative outcomes. For example, it could theoretically
enhance viral clearance by purging viral RNA from the cell. Alter-
natively, it could have proviral effects by vesicular sequestration
of otherwise immunostimulatory RNA from the cytosolic RNA
sensing machinery of the cell. It is also conceivable that HCV-
RNA-containing exosomes might also transfer infectious viral
genomes to cells (e.g., hepatocytes) that are permissive for viral
replication, in which case it would facilitate cell-to-cell spread of
an infection that is unconstrained by a neutralizing antibody
response. Additional experiments will be required to test these
interesting hypotheses.
We are intrigued by the fact that although pDC activation is
exosome mediated, it requires cell-cell contact because un-
concentrated supernatants from either infected cells or SGR
cells do not trigger IFN-a production by pDCs (Takahashi
et al., 2010). This suggests that HCV-infected cells and SGR
cells secrete exosomes into the culture supernatant at con-
centrations that are below an excitatory threshold that could
be reached in the intercellular space during cell-cell contact.
This is corroborated by the fact that the maximal HCV/pDC
ratio achieved by the coincubation of unconcentrated SGR
cell supernatants with pDCs (i.e., 0.2–0.5 HCV genomes/
pDC) is not sufficient to trigger IFN-a production (data not
shown; Takahashi et al., 2010). In contrast, SGR-cell superna-
tant-derived exosome preparations containing at least 10-fold
higher HCV-RNA concentrations (i.e., HCV-RNA/pDC ratio of
at least 2) are required to trigger low-level pDC IFN-a produc-
tion, and at least 45 HCV-RNA copies per pDC are needed for
robust pDC activation (Figure 5D). Interestingly, whereas HCV
RNA was detectable by FISH in only 10%–15% of total
pDC, it was detectable in three times as many IFN-a-positive
pDCs (Figure 2D). The absence of HCV RNA in many IFN-
a-positive pDCs may imply that they were stimulated in a para-
crine fashion by IFN-a, as previously suggested (Takahashi
et al., 2010). Importantly, the detection of HCV RNA in 8.6%
of IFN-a-negative pDCs may suggest that either independent
subsets of pDCs are differentially responsive to the HCV-RNA
stimulus, or that a certain amount of time is needed so that
HCV RNA can trigger pDCs to produce enough IFN-a to be
detectable, and the pDCs were observed before that threshold
was reached.
The potential physiological relevance of the process
described in this report is supported by the facts that exo-
some-mediated cell-cell transmission of siRNA occurs between
hepatocytes in vivo (Pan et al., 2012), that HCV-RNA-containing
exosomes are detectable in the plasma of chronically HCV-
infected patients (Masciopinto et al., 2004), that pDCs are abun-
dant in HCV-infected liver (Lau et al., 2008), and that pDCs from
HCV-infected patients respond normally to HCV-infected cells
(Takahashi et al., 2010). Therefore, at least theoretically, pDC
IFN production triggered by exosomes released by neighboring
HCV-infected hepatocytes could occur during natural HCV
infection. Additional experiments will be necessary to formally
test this hypothesis.Cell HostIn summary, the current results illustrate a previously unsus-
pected aspect of the innate host response in which the vesic-
ular transport machinery in a virus-infected cell produces
immunostimulatory viral RNA-containing exosomes that are
transferred at close range to professional IFN-producing cells
whose ability to trigger an innate response is not opposed
because they are not permissive for infection. These results
may have broad implications for our understanding of the
host-virus relationship, because cell-cell-contact-dependent
and TLR7-dependent pDC activation is now known to extend
to cells that replicate alphaviruses (Takahashi et al., 2010), to
HIV infection (Lepelley et al., 2011), and to a wide variety of
human (e.g., Huh-7 and HeLa) and animal (e.g., NIH 3T3) cells
that are infected by lymphocytic choriomeningitis virus (S.W.,
K. Takahashi, B.B., U.G., J.C. de la Torre, and F.V.C., unpub-
lished data). The current results provide a compelling rationale
for examining the role of RNA-containing exosomes in the
delivery of these evolutionarily and structurally distinct viral
RNAs to pDCs.
EXPERIMENTAL PROCEDURES
Biological Materials
Unless otherwise indicated, a subclone of Huh-7.5.1 cells (Huh-7.5.1c2; Dreux
et al., 2009; Gastaminza et al., 2010; Pedersen et al., 2007) that were infected
by the JFH-1 infectious molecular clone of HCV and Huh-7.5.1c2 cells that
harbor the JFH-1 SGR (Kato et al., 2003) were used in this study. In selected
experiments, results were confirmed using Huh-7.5.1 cells from which the
Huh-7.5.1c2 cells were derived (Figures S1, S4, and S5), and the parental
Huh-7 cell line. All cells were maintained in Dulbecco’s modified Eagle’s
medium (Cellgro; Mediatech, Herndon, VA) supplemented with 10% fetal
bovine serum (Cellgro), 10 mM HEPES, 100 units/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine (Invitrogen, Carlsbad, CA) in 5% CO2
at 37C. Viral stocks of cell-culture adapted JFH-1 virus (D183; Zhong et al.,
2006) were prepared by infection of Huh-7.5.1c2 cells at a multiplicity of
infection (moi) of 0.01, as described previously (Dreux et al., 2009). pDCs
were isolated from 450 ml of blood from healthy adult human volunteers after
informed consent was obtained according to procedures approved by the
Scripps Research Institute Human Research Committee. Briefly, PBMCs
were isolated using Ficoll-Hypaque density centrifugation, and pDCs were
positively selected from PBMCs using BDCA-4-magnetic beads (MACS
Miltenyi Biotec, Auburn, CA) according to the manufacturer’s instructions.
The typical yields of PBMCs and pDCs were 500 3 106 and 2 3 106 cells,
respectively, with a typical purity of >95% pDCs. Isolated pDCs were main-
tained in RPMI 1640 medium (Cellgro) supplemented with 10% fetal bovine
serum, 10 mM HEPES, 100 units/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine, nonessential amino acids, and 1 mM sodium pyruvate at
37C/5% CO2. Detailed descriptions of the reagents and constructs are
provided in Supplemental Experimental Procedures.
Detection of HCV RNA in pDC/HCV-SGR Cell Cocultures
by FISH Analysis
After isolation, pDCs were cocultured with HCV-SGR cells for 20 hr at 37C.
After 4% paraformaldehyde fixation at room temperature and washing with
phosphate-buffered saline, HCV plus strand RNA was detected using a probe
set that targets a region between nucleotide positions 2733 and 4870 in the
JFH-1 genome (Panomics/Affymetrix, Santa Clara, CA) according to the
manufacturer’s instructions. For immunostaining, mouse anti-IFN-a (MACS
Miltenyi Biotec, Auburn, CA) was diluted at 2 mg/ml using blocking and
binding buffers as previously described (Dreux et al., 2009). Nuclei were
stained by Hoechst dye. Images were acquired with a Zeiss LSM 710 laser
scanning confocal microscope and analyzed with IMARIS (Bitplane Inc.) soft-
ware. Details regarding the simultaneous detection of HCV RNA and CD63,
CD81, and CHMP4B protein are provided in Supplemental Experimental
Procedures.& Microbe 12, 558–570, October 18, 2012 ª2012 Elsevier Inc. 565
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Figure 6. ESCRT Proteins Are Required for Production of the pDC-Activating Signal by HCV-SGR and HCV-Infected Cells
(A and B) The impact of shRNA-mediated CHMP4B downregulation, using two different shRNAs (#30 and #69, described in Table S1) (A) and shRNA-mediated
TSG101 downregulation (B) on expression of the corresponding proteins (upper panels), levels of IFN-a in HCV-SGR Huh-7.5.1c2 cell-pDC coculture super-
natants (middle panels), and intracellular HCV RNA in Huh-7.5.1c2 SGR cells (lower panels) was compared with HCV-SGR cells transduced with shRNA against
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Figure 7. ANXA2 Is Required for HCV-
Infected and SGR Cells to Trigger IFN-a
Production by pDCs
(A–C) shRNA-mediated downregulation of ANXA2
protein in HCV-SGR Huh-7.5.1c2 cells (A) strongly
reduced IFN-a production by cocultured pDCs (B),
but had no impact on HCV replication (C). All
results were compared with ANXA2 shRNA-
transduced HCV-SGR Huh-7.5.1c2 cells that
ectopically express an shRNA-resistant variant of
ANXA2 (Rescue). Results are representative of two
independent experiments, each performed in
triplicate. NS, nonspecific band; MW, molecular
weight markers.
(D–G) Levels of downregulation of ANXA2
expression in HCV-infected Huh-7.5.1c2 cells (moi
of 5 for 48 hr) (D), IFN-a in HCV-infected cell-pDC
coculture supernatants (E), intracellular HCV RNA
in HCV-infected cells (F), and HCV infectious
particles in supernatants of the infected cells (G)
were compared with HCV-infected cells trans-
duced with an shRNA against GFP. HCV-negative
Huh-7.5.1c2 cells served as controls (cont cells).
The hatch marks (#) indicate results below the limit
of detection of the IFN-a ELISA (12.5 pg/ml). Error
bars represent the mean ± SD. See also Figure S4.
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Supernatants of 80% confluent HCV-SGR cells were cleared by 2,000 3 g
centrifugation for 20 min at 4C followed by filtration through a 0.22 mm filter
(Corning). Precleared supernatants were treated with 0.5% NP40, 100 mg/ml
RNase, and/or 0.4 U/ml RNase inhibitors for 1 hr at room temperature with
agitation. The efficiency of RNA extraction and quantitative RT-PCR (qRT-
PCR) was controlled by adding in vitro transcribed Xef1a (Xenopus transcrip-
tion factor 1a) to supernatants diluted in guanidinium thiocyanate citrate
buffer (GTC). Extracellular HCV-RNA, Xef1a, and GAPDH mRNA levels were
determined by qRT-PCR as previously described (Dreux et al., 2009). Extra-
and intracellular HCV-RNA levels were normalized for Xef1a and GAPDHGFP and an shRNA against an unrelated cellular protein (Atg4B) or nontransduced HCV-SGR cells (). HCV-n
cells). The hatchmarks (#) indicate results below the limit of detection of the IFN-aELISA (12.5 pg/ml). Results a
each performed in triplicate. Error bars represent the mean ± SD. NS, nonspecific band; PR, Ponceau red s
(C–E) CHMP4B and TSG101 downregulated Huh7.5.1c2 cells, infected by HCV (moi of 5 for 48 hr) were coc
and TSG101 expression (C), IFN-a in coculture supernatants (D, upper panel), intracellular HCV RNA (D, low
in supernatants of the infected cells (E) were compared with control HCV-infected cells transduced with s
served as controls (cont cells). Results are representative of two independent experiments, each performed in
also Figure S3.
Cell Host & Microbe 12, 558–570,RNA levels, respectively. The sequences of the
primers are described in Table S1. A detailed
description of the procedure used for northern
blot analysis is provided in Supplemental Experi-
mental Procedures.
Exosome Isolation
Supernatants were precleared by sequential low-
and high-speed centrifugation as follows: Briefly,
supernatants of 80% confluent HCV-SGR cells
were harvested twice (2 hr apart) and clarified by
centrifugation at 2,000 3 g for 20 min (4C),
yielding supernatants that were further clarified
by centrifugation at 10,000 3 g for 30 min (4C).
Exosomes in the clarified supernatants were then
pelleted at 110,000 3 g for 2 hr at 4C using
a SW28 rotor, as previously described (The´ry et al., 2006). The pelleted
exosome preparations were resuspended in exosome-depleted medium.
Approximately 0.25–0.5 mg of exosomal proteins were usually obtained from
1–2 3 106 cells. For each exosome isolation, the purity of the preparation
was determined by western blot analysis, as described in Supplemental
Experimental Procedures.
Downregulation by Lentivirus Vector-Based shRNA Transduction
and Expression Rescue Assay
Lentivirus vector-based shRNA was produced as described previously (Dreux
et al., 2009) and details are provided in Supplemental Experimentalegative Huh-7.5.1c2 cells served as controls (cont
re representative of two independent experiments,
taining; MW, molecular weight marker.
ultured with pDCs for 20 hr. The levels of CHMP4B
er panel), and titration of HCV infectious particles
hRNA against GFP. Uninfected Huh-7.5.1c2 cells
triplicate. Error bars represent the mean ± SD. See
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Exosomes Transfer HCV RNA to pDCs and Trigger IFNProcedures. The sequences of the shRNA are provided in Table S1. ANXA2
expression was rescued by transduction of ANAX2 downregulated cells with
a murine leukemia virus-based vector that permits expression of an ANXA2-
shRNA resistant cDNA. Details are provided in Supplemental Experimental
Procedures.Coculture Experiments
Unless otherwise indicated, 23 105 HCV-SGR cells, infected cells, or parental
cells were cocultured with 2 3 104 pDCs in 96-well round-bottom plates in
a 37C/5% CO2 incubator. Twenty hours later, cell-culture supernatants
were collected and IFN-a levels were measured with the use of a commercially
available ELISA kit (PBL Interferon Source, Piscataway, NJ) according to the
manufacturer’s instructions.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.chom.2012.08.010.ACKNOWLEDGMENTS
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